[
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Corporate Training Industry Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2019-2024", "dates": ["2020-10-17T21:30:00Z"], "links": "https://www.businesswire.com/news/home/20201017005012/en/Global-Corporate-Training-Industry-Services-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2019-2024", "content": "LONDON--( )--The Global Corporate Training Industry Services market will register an incremental spend of about $7 billion, growing at a CAGR of 9.00% during the five-year forecast period. A targeted strategic approach to Global Corporate Training Industry Services sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global Corporate Training Industry Services market. The report also aids buyers with relevant Global Corporate Training Industry Services pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global Corporate Training Industry Services procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Alnylam erh\u00e4lt positive CHMP-Stellungnahme f\u00fcr OXLUMO\u2122 (Lumasiran) f\u00fcr die Behandlung der prim\u00e4ren Hyperoxalurie Typ 1 in allen Altersgruppen", "dates": ["2020-10-17T14:48:00Z"], "links": "https://www.businesswire.com/news/home/20201017005010/de", "content": "CAMBRIDGE, Mass.--( )--Wie Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das f\u00fchrende Unternehmen f\u00fcr RNAi-Therapeutika, heute mitteilte, hat der Ausschuss f\u00fcr Humanarzneimittel (CHMP) der Europ\u00e4ischen Arzneimittelagentur (EMA) eine positive Stellungnahme abgegeben, in der die Zulassung von Lumasiran empfohlen wird. Lumasiran ist ein RNAi-Therapeutikum, das auf die mRNA der Hydroxys\u00e4ure-Oxidase 1 (HAO1)\u00a0\u2013 die f\u00fcr die Glykolat-Oxidase (GO) kodiert\u00a0\u2013 abzielt und f\u00fcr die Behandlung der prim\u00e4ren Hyperoxalurie Typ 1 (PH1) entwickelt wird. Nach der Zulassung durch die Europ\u00e4ische Kommission soll Lumasiran in Europa unter dem Markennamen OXLUMO\u2122 vertrieben werden.\n \nPH1 ist eine extrem seltene Erkrankung, die durch eine \u00fcberm\u00e4\u00dfige Oxalatproduktion gekennzeichnet ist und zu einer Nierenerkrankung im Endstadium (ESRD) und anderen systemischen Komplikationen f\u00fchren kann. PH1 betrifft etwa 3,5 bis 4 Personen pro Million in Europa und den USA. Die Heterogenit\u00e4t der Krankheitsmanifestation tr\u00e4gt oft zu Verz\u00f6gerungen bei der Diagnose bei, wobei die mediane Zeit bis zur Diagnose etwa sechs Jahre betr\u00e4gt. PH1 f\u00fchrt zu einer fortschreitenden Nierensch\u00e4digung, und Patienten mit fortgeschrittener Nierenerkrankung ben\u00f6tigen eine intensive Dialyse, um Abfallprodukte aus ihrem Blut zu filtern, bis sie in der Lage und berechtigt sind, eine duale oder sequentielle Leber/Nierentransplantation, ein invasives Verfahren, das mit einem hohen Morbidit\u00e4ts- und Mortalit\u00e4tsrisiko verbunden ist, sowie eine lebenslange Immunsuppression zu erhalten. \n \n\u201eDiese positive CHMP-Stellungnahme best\u00e4tigt das Potenzial von OXLUMO, den dringenden ungedeckten Bedarf zu erf\u00fcllen, der bei Patienten aller Altersgruppen besteht, die von einer prim\u00e4ren Hyperoxalurie Typ 1 betroffen sind. Da es keine zugelassenen pharmakologischen Behandlungsm\u00f6glichkeiten f\u00fcr PH1 gibt, halten wir dies f\u00fcr eine sehr ermutigende Nachricht f\u00fcr diejenigen, die mit dieser extrem seltenen, potenziell lebensbedrohlichen Krankheit leben, und ebenso f\u00fcr ihre Familien\u201c, so Brendan Martin, amtierender Leiter der Abteilung Europa, Kanada, Naher Osten und Afrika (CEMEA) von Alnylam Pharmaceuticals.\n \n\u201eMenschen mit PH1 erleben aufgrund der \u00dcberproduktion von Oxalat einen fortschreitenden R\u00fcckgang der Nierenfunktion, was zu einer Nierenerkrankung im Endstadium f\u00fchren kann. Die derzeitigen Behandlungsans\u00e4tze zielen darauf ab, das Fortschreiten der Niereninsuffizienz zu verz\u00f6gern, verhindern jedoch nicht die \u00dcberproduktion von Oxalat\u201c, berichtet Dr. Pushkal Garg, Chief Medical Officer von Alnylam Pharmaceuticals. \u201eIn klinischen Studien hat OXLUMO eine klinisch bedeutsame und anhaltende Reduktion von Harn- und Plasmaoxalat sowie ein ermutigendes Sicherheits- und Vertr\u00e4glichkeitsprofil gezeigt. Wir freuen uns, dass der CHMP den dringenden Bedarf an neuen Behandlungsmethoden f\u00fcr alle Altersgruppen erkannt hat und die ILLUMINATE-B-Ergebnisse in die anf\u00e4ngliche Zulassungsempfehlung aufgenommen hat.\u201c\n \nDie positive Stellungnahme beruht auf den Ergebnissen zur Wirksamkeit und Sicherheit von OXLUMO bei PH1-Patienten, einschlie\u00dflich der Daten aus den Phase-III-Studien ILLUMINATE-A und ILLUMINATE-B. Zu den wichtigsten prim\u00e4ren und sekund\u00e4ren Endpunkten geh\u00f6rten die Reduktion von Urin- und Plasmaoxalat sowie der Anteil der Patienten, bei denen eine Normalisierung oder Beinahe-Normalisierung des Urinoxalats als Reaktion auf OXLUMO im Vergleich zu Placebo erreicht wurde. Die Ergebnisse der ILLUMINATE-A-Zulassungsstudie wurden im Juni 2020 auf dem virtuellen internationalen Kongress der European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)  . \u00dcber die wichtigsten Ergebnisse der p\u00e4diatrischen Studie ILLUMINATE-B wurde im September  ; die Ergebnisse der Prim\u00e4ranalyse werden auf dem bevorstehenden virtuellen Jahreskongress der American Society of Nephrology (ASN) am 22. Oktober vorgestellt.\n \nOXLUMO wurde von der Europ\u00e4ischen Arzneimittel-Agentur EMA als unentbehrliches Arzneimittel (Priority Medicines, PRIME) anerkannt und erhielt in der EU den Status als Arzneimittel f\u00fcr seltene Leiden (Orphan Drug Designation). OXLUMO wurde von der Europ\u00e4ischen Arzneimittelagentur auch eine beschleunigte Beurteilung (Accelerated Assessment) zuerkannt, die an Medikamente vergeben wird, die als von gro\u00dfem Interesse f\u00fcr die \u00f6ffentliche Gesundheit und als therapeutische Innovation gelten, und die darauf abzielt, den Patienten neue Behandlungen schneller zur Verf\u00fcgung zu stellen. Alnylam reichte einen Antrag auf ein neues Medikament (New Drug Application, NDA) bei der amerikanischen Food and Drug Administration (FDA) ein. Die FDA hat eine Priorit\u00e4tspr\u00fcfung f\u00fcr den NDA bewilligt und den 3. Dezember 2020 als Aktionsdatum gem\u00e4\u00df dem Prescription Drug User Fee Act (PDUFA) festgelegt.\n \n \n \nOXLUMO ist ein RNAi-Therapeutikum, das auf Hydroxys\u00e4ure-Oxidase 1 (HAO1) zur Behandlung der prim\u00e4ren Hyperoxalurie Typ 1 (PH1) in allen Altersgruppen abzielt. HAO1 kodiert die Glykolat-Oxidase (GO)\u00a0\u2013 ein Enzym, das dem krankheitsverursachenden Defekt der PH1 vorgeschaltet ist. Durch die Stummschaltung von HAO1 und den Abbau des GO-Enzyms hemmt OXLUMO die Oxalatproduktion \u2013 dem Metaboliten, der die Pathophysiologie von PH1 unmittelbar beeinflusst. In der zulassungsrelevanten ILLUMINATE-A-Studie konnte gezeigt werden, dass OXLUMO die Oxalatkonzentration im Urin im Vergleich zu Placebo signifikant reduziert, wobei die Mehrheit der Patienten normale oder nahezu normale Werte erreichte. Injektionsstellenreaktionen (ISRs) waren die h\u00e4ufigste wirkstoffbedingte Nebenwirkung. In der p\u00e4diatrischen Phase-III-Studie ILLUMINATE-B zeigte OXLUMO ein Wirksamkeits- und Sicherheitsprofil, das mit dem in ILLUMINATE-A beobachteten \u00fcbereinstimmte. In OXLUMO kommt die Enhanced Stabilization Chemistry (ESC)-GalNAc-Konjugat-Technologie von Alnylam zum Einsatz, die die Wirksamkeit verst\u00e4rkt und Wirkdauer verl\u00e4ngert. OXLUMO wird durch subkutane Injektion einmal monatlich drei Monate lang verabreicht, dann einmal viertelj\u00e4hrlich in einer Dosis, die auf dem tats\u00e4chlichen K\u00f6rpergewicht basiert. Bei Patienten, die weniger als 10 kg wiegen, bleibt die Erhaltungsdosis monatlich. OXLUMO sollte von medizinischem Fachpersonal verabreicht werden. Die Sicherheit und Wirksamkeit von OXLUMO werden derzeit von der FDA gepr\u00fcft.\n \n \n \nBei der Studie ILLUMINATE-A   handelt es sich um eine 6-monatige, randomisierte, doppelblinde, placebokontrollierte, weltweit durchgef\u00fchrte, multizentrische Phase-III-Studie (mit 54-monatiger Verl\u00e4ngerungsphase) zur Bewertung der Wirksamkeit und Sicherheit von Lumasiran bei 39 Patienten mit dokumentierter PH1-Diagnose. Die Patienten wurden im Verh\u00e4ltnis 2:1 auf drei monatliche Dosen Lumasiran oder Placebo randomisiert, gefolgt von einer viertelj\u00e4hrlichen Erhaltungsdosis mit 3 mg/kg. Prim\u00e4rer Endpunkt der Studie war die prozentuale Ver\u00e4nderung der Oxalatausscheidung im 24-Stunden-Urin (Mittel der Monate 3-6) im Vergleich zum Ausgangswert (baseline) bei Patienten, die Lumasiran erhielten, im Vergleich zu Placebo. Die Behandlungsarme wurden bei der Randomisierung basierend auf der mittleren Oxalatkonzentration im 24-Stunden-Urin bei der Voruntersuchung stratifiziert (\u2264 1,7 oder > 1,7 mmol/24 Std./1,73 m ). Die wichtigsten sekund\u00e4ren und exploratorischen Endpunkte waren dahingehend ausgelegt, weiterere Messgr\u00f6\u00dfen wie Urinoxalat, Plasmaoxalat, gesch\u00e4tzte glomerul\u00e4re Filtrationsrate (eGFR), Nephrokalzinose, Nierensteinereignissen sowie Sicherheit und Vertr\u00e4glichkeit bewerten zu k\u00f6nnen.\n \n \n \nBei der Studie ILLUMINATE-B   eine sechsmonatige, einarmige, offene, multizentrische Phase-III-Studie (mit 54-monatiger Verl\u00e4ngerungsphase), in die 18 Patienten mit PH1 unter sechs Jahren aufgenommen wurden. Lumasiran wurde nach einem gewichtsabh\u00e4ngigen Dosierungsschema verabreicht. Patienten unter 10 kg K\u00f6rpergewicht erhielten drei monatliche Anfangsdosen von Lumasiran mit 6 mg/kg, gefolgt von monatlichen Erhaltungsdosen mit 3 mg/kg; Patienten mit einem K\u00f6rpergewicht von 10 kg oder mehr, aber weniger als 20 kg, erhielten drei monatliche Anfangsdosen mit 6 mg/kg, gefolgt von viertelj\u00e4hrlichen Erhaltungsdosen; Patienten \u00fcber 20 kg K\u00f6rpergewicht erhielten drei monatliche Anfangsdosen mit 3 mg/kg, gefolgt von viertelj\u00e4hrlichen Erhaltungsdosen. Der prim\u00e4re Wirksamkeitsendpunkt der Studie war die prozentuale Ver\u00e4nderung des Oxalat:Kreatinin-Verh\u00e4ltnisses im Punkturin im Durchschnitt der Monate 3 bis 6 gegen\u00fcber dem Ausgangswert im Monat 6. Die wichtigsten sekund\u00e4ren und exploratorischen Endpunkte waren dahingehend ausgelegt, weitere Messgr\u00f6\u00dfen wie Urinoxalat, Plasmaoxalat, gesch\u00e4tzte glomerul\u00e4re Filtrationsrate (eGFR), Nephrokalzinose, Nierensteinereignissen sowie Sicherheit und Vertr\u00e4glichkeit bewerten zu k\u00f6nnen.\n \n \n \nPH1 ist eine extrem seltene Erkrankung, bei der die \u00fcberm\u00e4\u00dfige Oxalatproduktion zu einer Ablagerung von Calciumoxalatkristallen in den Nieren und in den Harnwegen f\u00fchrt, was wiederum die Bildung schmerzhafter und wiederkehrender Nierensteine sowie Nephrokalzinose verursachen kann. Durch die Kombination von Nephrotoxizit\u00e4t durch das Oxalat, Ablagerungen von Calciumoxalat in den Nieren und Obstruktion der Harnwege durch Calciumoxalatsteine werden die Nieren gesch\u00e4digt. Die beeintr\u00e4chtigte Nierenfunktion verschlimmert die Erkrankung, weil das \u00fcbersch\u00fcssige Oxalat nicht mehr wirksam ausgeschieden werden kann, was zu einer Ansammlung und Kristallisierung in Knochen, Augen, Haut und Herz mit schwerer Krankheits- oder Todesfolge f\u00fchren kann. Die Behandlungsm\u00f6glichkeiten sind derzeit begrenzt und umfassen eine h\u00e4ufige Dialyse oder kombinierte Organtransplantationen von Leber und Nieren, ein Verfahren mit hoher Morbidit\u00e4tsrate, das durch eine begrenzte Organverf\u00fcgbarkeit gekennzeichnet ist. Zwar spricht eine kleine Minderheit von Patienten auf eine Vitamin B6-Therapie an, aber es gibt keine zugelassenen pharmakologischen Therapien f\u00fcr PH1.\n \n \n \nRNAi (RNA-Interferenz) ist ein nat\u00fcrlicher, zellul\u00e4rer Prozess zur Regulation bis hin zur Abschaltung von Genen. RNAi stellt derzeit einen der vielversprechendsten und am schnellsten voranschreitenden Forschungsbereiche in Biologie und Arzneimittelentwicklung dar. Ihre Entdeckung wurde begr\u00fc\u00dft als ein bedeutender wissenschaftlicher Durchbruch, der vielleicht einmal pro Dekade erreicht wird, und 2006 durch die Verleihung des Nobelpreises f\u00fcr Physiologie oder Medizin ausgezeichnet. Durch die Nutzung des nat\u00fcrlichen biologischen Prozesses der RNAi in unseren Zellen ist nun eine neue Klasse von Medikamenten, die als RNAi-Therapeutika bezeichnet werden, Realit\u00e4t geworden. Kleine interferierende RNA (small interfering RNA, siRNA), die Molek\u00fcle, die RNAi vermitteln und Bestandteil der therapeutischen RNAi-Plattform von Alnylam sind, funktionieren auf einer den heutigen Medikamenten vorgelagerten Ebene durch wirksame Herunterregulierung der Messenger-RNA (mRNA) \u2013 \u00dcbertr\u00e4ger der genetischen Information, die die krankheitsausl\u00f6senden Proteine kodiert \u2013 und verhindern auf diese Weise deren Bildung. Es handelt sich hier um einen bahnbrechenden Ansatz mit dem Potenzial, die Versorgung von Patienten mit genetischen und anderen Erkrankungen zu verbessern.\n \n \n \nAlnylam (Nasdaq: ALNY) ist f\u00fchrend bei der Translation der RNA-Interferenz (RNAi) in eine neue Klasse innovativer Medikamente, die das Potenzial besitzen, das Leben von Menschen, die an seltenen genetischen, kardiometabolischen, hepatischen, infekti\u00f6sen Krankheiten oder Erkrankungen des zentralen Nervensystems/ der Augen leiden, grundlegend zu ver\u00e4ndern. Basierend auf wissenschaftlichen Erkenntnissen, die mit dem Nobelpreis ausgezeichneten wurden, stellen RNAi-Therapeutika einen starken, klinisch validierten Ansatz f\u00fcr die Behandlung von Erkrankungen mit einem hohen unerf\u00fcllten medizinischen Bedarf dar. Alnylam wurde 2002 gegr\u00fcndet und verwirklicht mit einer starken Plattform f\u00fcr RNAi-Therapeutika eine mutige Vision, um wissenschaftliche M\u00f6glichkeiten in die Realit\u00e4t umzusetzen. Die kommerziellen RNAiTherapeutika von Alnylam sind ONPATTRO   (Patisiran), das in den USA, der EU, Kanada, Japan, der Schweiz und Brasilien zugelassen ist, und GIVLAARI  (Givosiran), das in den USA, der EU und Brasilien zugelassen ist. Alnylam verf\u00fcgt \u00fcber eine umfangreiche Pipeline von Pr\u00fcfpr\u00e4paraten, darunter sechs Produktkandidaten, die sich in der sp\u00e4ten Entwicklungsphase befinden. Alnylam hat sich mit seiner Strategie \u201eAlnylam 2020\u201c zum Ziel gesetzt, in den n\u00e4chsten Jahren zu einem weltweit f\u00fchrenden biopharmazeutischen Unternehmen zu werden. Dazu geh\u00f6rt es, eine nachhaltige Pipeline von Medikamenten auf RNAi-Basis aufzubauen, um die Bed\u00fcrfnisse von Patienten mit begrenzten ungen\u00fcgenden Behandlungsm\u00f6glichkeiten zu erf\u00fcllen. Alnylam hat seinen Hauptsitz in Cambridge, Massachusetts (USA).\n \n \n \nVerschiedene Aussagen in dieser Pressemitteilung bez\u00fcglich der zuk\u00fcnftigen Erwartungen, Pl\u00e4ne und Aussichten von Alnylam, unter anderem Alnylams Ansichten bez\u00fcglich der Sicherheit und Wirksamkeit von Lumasiran, wie sie in den Phase-III-Studien ILLUMINATE-A und ILLUMINATE-B gezeigt wurden, und des Potenzials von Lumasiran, dringende unerf\u00fcllte Bed\u00fcrfnisse von PH1-Patienten aller Altersgruppen zu erf\u00fcllen und einen g\u00fcnstigen Einfluss auf die Manifestationen der PH1-Krankheit zu haben, Alnylams Erwartungen hinsichtlich der Auswirkungen der positiven Stellungnahme, in der die Zulassung von Lumasiran durch den CHMP empfohlen wird, und des Zeitplans f\u00fcr die m\u00f6gliche Zulassung von Lumasiran durch die Europ\u00e4ische Kommission nach der positiven Stellungnahme des CHMP, [Alnylams Erwartungen hinsichtlich des Zeitplans f\u00fcr die \u00dcberpr\u00fcfung der Lumasiran-NDA durch die FDA], Alnylams Pl\u00e4ne, Lumasiran f\u00fcr Patienten mit PH1 weltweit zur Verf\u00fcgung zu stellen, und die Erwartungen hinsichtlich der weiteren Umsetzung der Strategie \u201eAlnylam 2020\u201c f\u00fcr die Weiterentwicklung und Vermarktung von RNAi-Therapeutika sind zukunftsgerichtete Aussagen im Sinne der Safe-Harbor-Bestimmungen des Private Securities Litigation Reform Act von 1995. Die tats\u00e4chlichen Ergebnisse und zuk\u00fcnftigen Pl\u00e4ne k\u00f6nnen sich von den in den hier enthaltenen zukunftsgerichteten Aussagen aufgrund verschiedener wichtiger Risiken, Unw\u00e4gbarkeiten und anderer Faktoren wesentlich unterscheiden. Zu diesen geh\u00f6ren unter anderem die direkten oder indirekten Auswirkungen der globalen Pandemie COVID-19 oder einer zuk\u00fcnftigen Pandemie, wie z. B. Umfang und Dauer des Ausbruchs, staatliche Ma\u00dfnahmen und restriktive Ma\u00dfnahmen, die als Reaktion darauf ergriffen wurden, wesentliche Verz\u00f6gerungen bei der Diagnose seltener Krankheiten, Beginn oder Fortsetzung der Behandlung von Krankheiten, die mit Alnylam-Produkten behandelt werden, oder bei der Patientenaufnahme in klinische Studien, potenzielle Unterbrechungen in der Versorgungskette und andere potenzielle Auswirkungen auf das Gesch\u00e4ft von Alnylam, die Wirksamkeit oder P\u00fcnktlichkeit der von Alnylam ergriffenen Ma\u00dfnahmen zur Milderung der Auswirkungen der Pandemie sowie Alnylams F\u00e4higkeit, Pl\u00e4ne zur Gesch\u00e4ftskontinuit\u00e4t umzusetzen, um Unterbrechungen zu beheben, die durch COVID-19 oder eine zuk\u00fcnftige Pandemie verursacht werden; die F\u00e4higkeit von Alnylam, neue Arzneimittelkandidaten zu entdecken und zu entwickeln, die pr\u00e4klinischen und klinischen Ergebnisse f\u00fcr seine Produktkandidaten, die m\u00f6glicherweise nicht repliziert werden oder sich bei anderen Menschen oder in weiteren Studien nicht wiederholen, oder die anderweitig keine weitere Entwicklung von Produktkandidaten f\u00fcr eine spezifische Indikation oder allgemein rechtfertigen; Handlungen oder Bescheide der Zulassungsbeh\u00f6rden, die sich auf das Design, die Initiierung, Terminierung, Fortsetzung und/oder den Fortschritt von klinischen Studien auswirken oder zur Notwendigkeit weiterer pr\u00e4klinischer und/oder klinischer Untersuchungen f\u00fchren k\u00f6nnen; Verz\u00f6gerungen, Unterbrechungen oder Fehler in der Herstellung und Lieferung seiner Produktkandidaten oder vermarkteten Produkte einschlie\u00dflich Lumasiran; die Erteilung, die Aufrechterhaltung und der Schutz von Rechten an geistigem Eigentum; Fragen des geistigen Eigentums einschlie\u00dflich m\u00f6glicher Patentstreitigkeiten in Bezug auf seine Plattform, Produkte oder Produktkandidaten; die Erlangung der beh\u00f6rdlichen Zulassung f\u00fcr seine Produktkandidaten, einschlie\u00dflich Lumasiran, und die Aufrechterhaltung der beh\u00f6rdlichen Zulassung sowie Preisgestaltung und Kosten\u00fcbernahme f\u00fcr seine Produkte, einschlie\u00dflich ONPATTRO und GIVLAARI; Fortschritte beim weiteren Aufbau einer kommerziellen Infrastruktur au\u00dferhalb der USA; Erfolg bei Markteinf\u00fchrung, Vermarktung und Vertrieb seiner zugelassenen Produkte einschlie\u00dflich ONPATTRO und GIVLAARI weltweit und das Erreichen der Nettoprodukteinnahmen f\u00fcr ONPATTRO innerhalb der erwarteten Spanne im Jahr 2020; die F\u00e4higkeit von Alnylam, die Indikation f\u00fcr ONPATTRO in Zukunft erfolgreich zu erweitern; Wettbewerbsdruck durch andere, die eine \u00e4hnliche Technologie wie Alnylam verwenden und andere, die Produkte f\u00fcr \u00e4hnliche Anwendungen entwickeln; die F\u00e4higkeit von Alnylam, sein Wachstum und seine Betriebsausgaben durch die Umsetzung weiterer Disziplin im Betrieb zur D\u00e4mpfung der Ausgaben innerhalb der von Alnylam vorgegebenen Planung zu halten, und seine F\u00e4higkeit, in Zukunft ein selbsttragendes Finanzprofil ohne die Notwendigkeit einer zuk\u00fcnftigen Eigenkapitalfinanzierung zu erreichen; die F\u00e4higkeit von Alnylam, strategische Gesch\u00e4ftsallianzen und neue Gesch\u00e4ftsinitiativen aufzubauen und aufrechtzuerhalten; die Abh\u00e4ngigkeit von Alnylam von Dritten, einschlie\u00dflich Regeneron, bei Entwicklung, Herstellung und Vertrieb bestimmter Produkte, einschlie\u00dflich Augen- und ZNS-Produkte, und Ironwood bei der Unterst\u00fctzung der Aufkl\u00e4rung \u00fcber und der F\u00f6rderung von GIVLAARI und Vir f\u00fcr die Entwicklung von ALN-COV und anderen potenziellen RNAi-Therapeutika, die auf SARS-CoV-2 und Wirtsfaktoren f\u00fcr SARS-CoV-2 abzielen; der Ausgang von Rechtsstreitigkeiten; das Risiko staatlicher Untersuchungen und unerwarteter Ausgaben sowie die Risiken, die ausf\u00fchrlich in den \u201eRisk Factors\u201d dargelegt wurden, die zusammen mit dem letzten Alnylam-Jahresbericht auf dem Formular 10-K bei der Securities and Exchange Commission (SEC) und in anderen Dokumenten von Alnylam bei der SEC eingereicht wurden. Alle zukunftsgerichteten Aussagen spiegeln nur die am Tag der Ver\u00f6ffentlichung geltenden Einsch\u00e4tzungen von Alnylam wider und gelten nicht f\u00fcr einen sp\u00e4teren Zeitpunkt als das Datum der Ver\u00f6ffentlichung dieser Pressemitteilung. Au\u00dferhalb des gesetzlich vorgegebenen Rahmens lehnt Alnylam ausdr\u00fccklich jegliche Verpflichtung zur Aktualisierung von zukunftsgerichteten Aussagen ab.\n \nDie Ausgangssprache, in der der Originaltext ver\u00f6ffentlicht wird, ist die offizielle und autorisierte Version. \u00dcbersetzungen werden zur besseren Verst\u00e4ndigung mitgeliefert. Nur die Sprachversion, die im Original ver\u00f6ffentlicht wurde, ist rechtsg\u00fcltig. Gleichen Sie deshalb \u00dcbersetzungen mit der originalen Sprachversion der Ver\u00f6ffentlichung ab.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "The Return of Antelope Herds to Central Oregon\u2019s Longview Ranch", "dates": ["2020-10-17T06:59:00Z"], "links": "https://www.businesswire.com/news/home/20201016005002/en/The-Return-of-Antelope-Herds-to-Central-Oregon%E2%80%99s-Longview-Ranch", "content": "KIMBERLY, Ore.--( )--Located in Central Oregon\u2019s picturesque John Day River Territory,   maintains   of diverse landscape. While the primary purpose of the property is raising grass-fed cattle, Longview Ranch has passionately undertaken sustainable practices that show respect for the land.\n \nSeveral years ago, the area was not well known for its well pronghorn antelope population. As a result of Longview Ranch\u2019s responsible land-use practices, the property has recently seen a  . Now anywhere from 100 to 250 antelope can be found roaming the property.\n \nLongview Ranch prioritizes living in harmony with the land and showing continued respect for the creatures that inhabit the region.\n \n \n \nLocated along Central Oregon\u2019s historic Route 19 in Kimberly, Longview Ranch maintains  . Eight miles of the John Day River flows through the middle of the property, which operates primarily for the purpose of raising grass-fed cattle. With three tributaries sharing annual steelhead runs, Longview Ranch also manages 25,000 acres of Bureau of Land Management (BLM) grazing grounds and 485 acres of irrigated hay producing land, which is home to 800 mother cows and 50 bulls.\n \nLongview Ranch remains committed to responsible, sustainable land-use practices, and has completed a restoration project along the   to reestablish vegetation. Each year, the property invests in the prevention of noxious weeds that could harm the land at Longview Ranch, as well as its neighboring farms. The ranch also partakes in best practices regarding wildlife, limiting hunting on property and ensuring   have a refuge. Additionally, while the area is not known for large numbers of antelope, in thanks to the integrity of the property, more than  .\n \nLongview Ranch has also has a rich history of giving back to its community, making annual donations to the Grant County 4-H and Union County Chapter of the Rocky Mountain Elk Foundation.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Growing Momentum as New Poll Puts Brock Pierce, Independent Candidate for President of the United States of America, in Third Place in New York ", "dates": ["2020-10-17T16:14:00Z"], "links": "https://www.businesswire.com/news/home/20201017005013/en/Growing-Momentum-as-New-Poll-Puts-Brock-Pierce-Independent-Candidate-for-President-of-the-United-States-of-America-in-Third-Place-in-New-York", "content": "NEW YORK--( )--Brock Pierce, the independent candidate for President of the United State of America, is gaining steam as the third choice for voters in the November 3rd presidential election, as a new poll puts him in third place in the state of New York.\n \nThe Siena College   of 504 likely voters shows Pierce behind President Donald Trump with six percent of support among independent-minded voters across New York. The survey also shows Pierce picking up more support in New York\u2019s suburbs and voters aged 35-54.\n \nPierce and his running mate, Karla Ballard, are on the ballot in New York on the Independence Party line after the unanimous endorsement of the Independence Party of New York at its presidential nominating convention this past August.\n \n \n \nPierce, 39, grew up as a successful child-actor, starring in 11 Hollywood films, including Disney\u2019s   and  , before becoming a successful entrepreneur as a young man. Inspired by technology and innovation, Pierce co-founded, advised, and funded more than 100 businesses and became a pioneer in blockchain technology and digital currencies. Pierce is a philanthropist, committed to improving people's lives, even while stepping into the political arena. Pierce announced his bid for the presidency on July 4th, America\u2019s Independence Day.\n \n \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Emergency Lighting Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T20:30:00Z"], "links": "https://www.businesswire.com/news/home/20201017005009/en/Global-Emergency-Lighting-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Global Emergency Lighting market will register an incremental spend of about $1 billion, growing at a CAGR of 3.71% during the five-year forecast period. A targeted strategic approach to Global Emergency Lighting sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global Emergency Lighting market. The report also aids buyers with relevant Global Emergency Lighting pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global Emergency Lighting procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Electric Motors Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T20:00:00Z"], "links": "https://www.businesswire.com/news/home/20201017005008/en/Global-Electric-Motors-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Global Electric Motors market will register an incremental spend of about $45 billion, growing at a CAGR of 6.00% during the five-year forecast period. A targeted strategic approach to Global Electric Motors sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global Electric Motors market. The report also aids buyers with relevant Global Electric Motors pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global Electric Motors procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System\u2019s Bioresorbable Coated Drug-Eluting Coronary Stent", "dates": ["2020-10-17T16:00:00Z"], "links": "https://www.businesswire.com/news/home/20201017005003/en/OPTIMIZE-Study-Reports-Lowest-TLR-Ever-Achieved-in-an-Investigational-Device-Exemption-IDE-Study-With-Svelte-Medical-System%E2%80%99s-Bioresorbable-Coated-Drug-Eluting-Coronary-Stent", "content": "NEW PROVIDENCE, N.J.--( )--The Svelte  Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and secondary endpoint outcomes of the OPTIMIZE IDE study, designed to assess the safety and efficacy of the Svelte DES Integrated Delivery System (SLENDER IDS ) and Rapid Exchange (DIRECT RX ) platforms, were presented today during the Late-Breaking Trials session at TCT Connect.\n \nOPTIMIZE randomized 1,639 subjects (1:1 SLENDER IDS or DIRECT RX DES vs. Xience  or Promus  DES) at 74 investigative sites in the US, Japan and Europe in support of US and Japan regulatory approvals. Under the prespecified study statistical analysis plan, the threshold for non-inferiority of 1 year Target Lesion Failure (TLF) using an absolute non-inferiority margin was not quite met (p=0.034 with 0.025 the prespecified threshold for non-inferiority). Unprecedented Target Vessel Myocardial Infarction (TVMI) rates of 8.8% were observed across both treatment groups, driven by the frequent use of high-sensitivity troponin biomarkers during peri-procedural assessments, leading to overall TLF of 9.9%, nearly double the expected rate and effectively underpowering the study. Non-inferiority of the Svelte DES compared to the Xience and Promus DES was clearly established in independent analyses of the OPTIMIZE results using either a comparable relative non-inferiority margin with the protocol definition of MI (p=0.009), or the SCAI definition of MI (p=0.003), which specifically accounts for high-sensitivity troponin use in the assessment of peri-procedural TVMI.\n \nDean Kereiakes, M.D., F.A.C.C., the Medical Director at The Christ Hospital, Lindner Research Center in Cincinnati, Ohio and co-principal investigator of the OPTIMIZE study stated, \u201cThe Svelte DES went head-to-head against the gold standard for DES and demonstrated exceptionally low TLR and stent thrombosis rates at 1 year. I regard the high TVMI rates observed in this study as artifact. When nearly 1 in 3 subjects assessed using high-sensitivity troponin assays is counted as TVMI across both treatment groups (including previously studied and highly regarded DES as the control), it is clear the protocol definition of TVMI, and not clinically meaningful TVMI, plagued this study.\u201d\n \n\u201cThe high TLF reported in both OPTIMIZE treatment groups is driven by the 25% of study subjects assessed peri-procedurally with high-sensitivity-troponin. These subjects accounted for 80% of all study TVMIs, yet 96% of them had no ECG changes and 88% were discharged post-procedure without delay, data that are not indicative of true clinical TVMI,\u201d added Sunil Rao, M.D., F.A.C.C., Professor of Medicine at Duke University in Durham, North Carolina and co-principal investigator of the OPTIMIZE study. \u201cWith definition-driven TVMI placed into appropriate context, it\u2019s exciting to see the exceptional clinical outcomes achieved in OPTIMIZE with 79% of subjects undergoing TRI. The low profile of the Svelte DES, and especially SLENDER IDS, facilitates TRI. The significantly lower access site hematoma rates and strong 1 year clinical results in TRI subjects should be of interest to radial specialists seeking to downsize catheters and improve patient care.\u201d\n \nDirect stenting was undertaken in 30% of OPTIMIZE subjects, with 96% device success rates observed. Ronald Caputo, M.D., F.A.C.C., an interventional cardiologist at Levine Heart & Wellness in Naples, Florida and top-5 user of SLENDER IDS for direct stenting in the OPTIMIZE study stated, \u201cSLENDER IDS offers a unique low-profile option especially attractive to radial operators. It and DIRECT RX are extremely deliverable stents. I was very impressed with their performance during the study and exceptional 1 year clinical outcomes.\u201d Investigators with prior experience direct stenting with SLENDER IDS in Europe also realized significant reductions in procedure, device and fluoroscopy times, as well as radiation exposure, compared with direct stenting using control DES.\n \nSLENDER IDS and DIRECT RX utilize the same low profile, highly conformable stent with a new class of bioresorbable sirolimus-eluting drug carrier designed to minimize inflammation and promote vessel healing. Both SLENDER IDS and DIRECT RX hold CE Mark certification and are commercially available in Europe.\n \n\u201cWe are deeply grateful to each and every one of the patients, investigative team members and support personnel contributing to the OPTIMIZE study. Our highly differentiated platforms bring a new and unique approach to coronary stenting which improves procedural efficiency while enhancing patient outcomes and comfort, delivering value to all constituents \u2013 patients, physicians, providers and payers,\u201d said Jack Darby, President and CEO of Svelte Medical Systems.\n \n \n \nHeadquartered in New Providence, New Jersey, Svelte Medical Systems ( ) is a privately-held company engaged in the development of highly deliverable balloon expandable stents. Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits, are forward-looking statements. A number of risks and uncertainties, such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the company\u2019s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings, could cause actual events to adversely differ from the expectations indicated in these forward-looking statements.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global PET Packaging Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2019-2024", "dates": ["2020-10-17T21:00:00Z"], "links": "https://www.businesswire.com/news/home/20201017005011/en/Global-PET-Packaging-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2019-2024", "content": "LONDON--( )--The Global PET Packaging market will register an incremental spend of about $16 billion, growing at a CAGR of 4.00% during the five-year forecast period. A targeted strategic approach to Global PET Packaging sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global PET Packaging market. The report also aids buyers with relevant Global PET Packaging pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfill their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global PET Packaging procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Alnylam riceve un\u2019opinione positiva dal CHMP per OXLUMO\u2122 (lumasiran) per il trattamento dell\u2019iperossaluria primaria di tipo 1 in tutti i gruppi di et\u00e0", "dates": ["2020-10-17T06:50:00Z"], "links": "https://www.businesswire.com/news/home/20201016005704/it", "content": "CAMBRIDGE, Massachusetts--( )--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), l\u2019azienda leader nello sviluppo di RNAi terapeutiche, oggi ha annunciato che il Committee for Medicinal Products for Human Use (CHMP) dell\u2019Agenzia europea per i medicinali (EMA) ha adottato un\u2019opinione positiva raccomandando l\u2019approvazione del lumasiran, una RNAi terapeutica sperimentale che ha come bersaglio l\u2019idrossiacido ossidasi 1 (HAO1) mRNA - codifica della glicolata ossidasi (GO) - in sviluppo per il trattamento dell\u2019iperossaluria primaria di tipo 1 (PH1).\n \nIl testo originale del presente annuncio, redatto nella lingua di partenza, \u00e8 la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit\u00e0 del lettore e devono rinviare al testo in lingua originale, che \u00e8 l'unico giuridicamente valido.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Midea Awarded by UNIDO for Environmental Protection Efforts", "dates": ["2020-10-17T07:55:00Z"], "links": "https://www.businesswire.com/news/home/20201017005005/en/Midea-Awarded-by-UNIDO-for-Environmental-Protection-Efforts", "content": "BEIJING--( )--Midea (SZSE:000333), the world\u2019s No.1 air treatment company was recently awarded by the United Nations Industrial Development Organization (UNIDO) for its outstanding contribution to environmental protection.\n \nUNIDO \u201cwould like to express its highest appreciation to Midea, for their ongoing efforts to develop, manufacture and introduce to the market residential air conditioners that meet the highest environmental standards,\u201d read the Certificate of Outstanding Contribution Award presented by UNIDO.\n \nAuthorized by Mr Ole who was unable to attend the ceremony due to COVID-19, Ma Jian, the deputy representative of UNIDO for China, presented the award and showed his congratulations to Midea. \u201cIn the future, we sincerely expect more cooperation between Midea and the UNIDO to make more contributions to the global environmental protection together.\u201d\n \nOver the past 10 years, Midea has cooperated with UNIDO on a project aiming at replacing HCFC-22, an environmentally harmful refrigerant, with propane (R-290), a natural substance, which contributes both directly and indirectly to the international community\u2019s fight against climate change by introducing the optimized refrigerant system.\n \nMidea\u2019s project of developing, producing and distributing products powered by such a system has phased out 13.2 tons of ozone-depleting potential and reduced 967,490 tons of CO2 equivalent emission per year, according to data from UNIDO.\n \n\u201cUNIDO would like to commend Midea\u2019s Management and committed staff for their vision to protect the environment and thank them for the excellent cooperation,\u201d wrote the award certificate wrote.\n \nAs a result of Midea\u2019s decade-long research and development efforts, the project demonstrates Midea\u2019s technical strength as well as its devotion to protecting the earth.\n \nMidea has put in more than $7 million in converting the production line to R-290-powered products. Eighty-three of its labs are now dedicated to researches around RAC with low GWP refrigerants. The company\u2019s heavy investment has won it more than 200 domestic and international patents in the field. And its R-290 products are widely recognized by the international community both as forerunners in environmental protection and as reliable choices with high efficiency and consistent performance.\n \nSince their introduction to the European market in 2014, Media\u2019s products have won multiple top industrial awards in China and beyond. The products are also widely welcomed in the market. More than 1,000,000 of Midea\u2019s R-290 air conditioners have entered the European market, with more than 200,000 already sold in China. With boosting needs, Midea\u2019s converted production line now has a production output of 750,000 units per year, according to UNIDO.\n \nMidea\u2019s carrying out and achieving success with the project are inseparable with its complete and large air conditioner production setup, long-term commitment to research and development and its determination to benefit the global environment.\n \nWith Midea being an industry leader and pioneer, its success has significant implications for the entire industry, recognized by UNIDO.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Medical Carts Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T04:10:00Z"], "links": "https://www.businesswire.com/news/home/20201016005360/en/Global-Medical-Carts-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Global Medical Carts market will register an incremental spend of about $1 billion, growing at a CAGR of 8.45% during the five-year forecast period. A targeted strategic approach to Global Medical Carts sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic. \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global Medical Carts market. The report also aids buyers with relevant Global Medical Carts pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global Medical Carts procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Ammonia Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T13:00:00Z"], "links": "https://www.businesswire.com/news/home/20201017005001/en/Ammonia-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Ammonia market will register an incremental spend of about $ 11 billion, growing at a CAGR of 3.65% during the five-year forecast period. A targeted strategic approach to Ammonia sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Ammonia market. The report also aids buyers with relevant Ammonia pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n \n \n \n \n \n \nThis Global Coke procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Protein Ingredient Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T14:00:00Z"], "links": "https://www.businesswire.com/news/home/20201017005002/en/Protein-Ingredient-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Protein Ingredient market will register an incremental spend of about $ 16 billion, growing at a CAGR of 7.45% during the five-year forecast period. A targeted strategic approach to Protein Ingredient sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Protein Ingredient market. The report also aids buyers with relevant Protein Ingredient pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n \n \n \n \n \n \nThis Global Coke procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Pharmaceutical Excipients Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T04:30:00Z"], "links": "https://www.businesswire.com/news/home/20201016005313/en/Global-Pharmaceutical-Excipients-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Global Pharmaceutical Excipients market will register an incremental spend of about $3 billion, growing at a CAGR of 7.39% during the five-year forecast period. A targeted strategic approach to Global Pharmaceutical Excipients sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global Pharmaceutical Excipients market. The report also aids buyers with relevant Global Pharmaceutical Excipients pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global Pharmaceutical Excipients procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global SEM Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024", "dates": ["2020-10-17T05:00:00Z"], "links": "https://www.businesswire.com/news/home/20201016005499/en/Global-SEM-Services-Market-Procurement-Intelligence-Report-with-COVID-19-Impact-Analysis-Global-Forecasts-2020-2024", "content": "LONDON--( )--The Global SEM Services market will register an incremental spend of about $102 billion, growing at a CAGR of 9.57% during the five-year forecast period. A targeted strategic approach to Global SEM Services sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic \n \n \n \n \n \nSpendEdge's reports   impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \nSeveral strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Global SEM Services market. The report also aids buyers with relevant Global SEM Services pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.\n \n \n \n :\n \n \n \n \n \nThis Global SEM Services procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n \n \n -  \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Gifts Retailing Market | Growing Popularity of Private-label Brands to Boost Market Growth | Technavio", "dates": ["2020-10-17T03:55:00Z"], "links": "https://www.businesswire.com/news/home/20201016005493/en/Global-Gifts-Retailing-Market-Growing-Popularity-of-Private-label-Brands-to-Boost-Market-Growth-Technavio", "content": "LONDON--( )--The global gifts retailing market size is poised to grow by USD 6.45 billion during 2020-2024, progressing at a CAGR of almost 2% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic.  \n \nThe gift retailing market is driven by the growing popularity of private-label brands. Private-label gifts are becoming a key focus area for retailers across the world. Retailers are selling different types of gifts under their private-label brands also to improve their profitability. Private-label products are priced lower than branded products. Hence, price-sensitive customers are more likely to purchase such gifts. Gift retailers such as supermarket chains have started allocating more shelf space to private-label offerings and are undertaking in-house marketing and promotional activities. The demand for private-label brands is expected to increase during the forecast period, which, in turn, is expected to support the growth of the global gifts retailing market, in terms of volume sales.\n \n \n \n \n \n \n \n \n \nExisting market vendors focus on distribution-channel expansion strategies to enhance their market reach. Omnichannel retailing and social-media marketing strategies positively impact the growth of the global gifts retailing market. Omnichannel retailing is executed through multiple retail channels. It is a combination of e-commerce, m-commerce, and brick-and-mortar retailing. Social media marketing enhances brand image, thereby impacting the customer base of the existing market vendors. Independent gift retailers, which have a minimal financial back-up, benefit significantly from social media marketing. Social media platforms enable the reception of quick consumer responses, which aid the marketers in planning their sales strategies. Hallmark Licensing, a prominent market vendor, has an impactful presence on YouTube, Facebook, Instagram, Pinterest, and Twitter. Amazon.com and Alibaba Group are the prominent e-commerce retailers that engage in gift retailing. Thus, distribution-channel expansions and social media marketing will propel the demand for gifts during the forecast period.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Scanning Electrochemical Microscopy Market | Growth to Accelerate at a CAGR of Almost 7% Through 2024 | Technavio", "dates": ["2020-10-17T03:00:00Z"], "links": "https://www.businesswire.com/news/home/20201016005496/en/Scanning-Electrochemical-Microscopy-Market-Growth-to-Accelerate-at-a-CAGR-of-Almost-7-Through-2024-Technavio", "content": "LONDON--( )--The scanning electrochemical microscopy (SECM) market size is set to grow by USD 41.9 million accelerating at a CAGR of almost 7%, during the period spanning over 2020-2024. One of the key factors driving growth is the miniaturization of electronic devices. The ongoing trend of miniaturization has led semiconductor manufacturers to focus on reducing the size of semiconductor wafers and increase the energy efficiency of ICs. The extensive use of SECM in research on corrosion is a significant trend that will further stimulate market growth. SECM is widely adopted for studying numerous factors, including electron transfer kinetics, surface microstructure, initiation and propagation of pitting, and the effectiveness of protective measures such as treatments, inhibitors, and coatings.\n \n \n \n \n \nTechnavio categorizes the global scanning electrochemical microscopy market as a part of the global life sciences tools and services market. The global life sciences and tools market covers products and companies engaged in the R&D of a variety of product categories, including capital equipment, instruments, accessories, and consumables that are used in the R&D of pharmaceuticals and biotechnology products, as well as the laboratory diagnosis of various diseases. It also covers life sciences-related services, including contract research, contract manufacturing, and contract sales.\n \nGrowth in the global life sciences tools and services market will be driven by the increase in the life expectancy of individuals worldwide.\n \n \n \n \n \nThe report segments the market by geography: APAC, Europe, MEA, North America, and South America. About 37% of the market\u2019s growth will originate from North America during the forecast period. This is due to the strong presence of large technology companies that use miniature semiconductors in various electronic products. Also, the presence of numerous research institutes in the region is contributing to the market growth. The US is the key market for scanning electrochemical microscopy in North America.\n \n \n \nThe AFM-SECM segment was leading the market in 2019. AFM-SECM has emerged as a versatile tool for simultaneous measurements of the topographical as well as electrochemical properties of various material surfaces with high spatial resolution. Besides, the growing number of clinical trials and research activities related to the development of the drug for the ongoing COVID-19 pandemic has further increased the use of the AFM-SECM approach. This report provides an accurate prediction of the contribution of all the segments to the growth of the scanning electrochemical microscopy market size.\n \n \n \nThe market is driven by the miniaturization of electronic devices. Electronic device manufacturers are focusing on the development of miniature devices as they consume less energy. This is increasing the use of completely novel types of tips in multi-functional biological SECM devices. Also, the development of miniaturized analytical systems for DNA analysis, immunoassays, and enzyme sensors have made the application areas of SECM more attractive for the optimization and the evaluation of detection strategies and the further characterization of sensing platforms. Thus, the miniaturization of electronic devices will positively influence market growth during the forecast period.\n \n \n \nThe price of commercially available standard potentiostats with low-current measurement capabilities is generally between USD 2,000 and USD 20,000. Many organizations do not have an adequate budget to meet such high capital expenditure. Also. several educational institutions and research organizations depend on funding from external agencies and their purchase decisions are dependent on the approval of the funding. These factors are hindering the adoption of the SECM technique.\n \n \n \nThis report provides information on revenue, organizational developments, and key go-to-market strategies of several leading scanning electrochemical microscopy companies, including:\n \n \n \n \n \n \n \n \n \nTechnavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.\n \nWith over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Virtualized Evolved Packet Core (vEPC) Market | Increasing Demand for VoLTE to Upheave Growth Through 2024 | Technavio", "dates": ["2020-10-17T03:15:00Z"], "links": "https://www.businesswire.com/news/home/20201016005495/en/Virtualized-Evolved-Packet-Core-vEPC-Market-Increasing-Demand-for-VoLTE-to-Upheave-Growth-Through-2024-Technavio", "content": "LONDON--( )--Set to grow by USD 17.51 billion during 2020-2024, Technavio\u2019s latest market research report estimates the virtualized evolved packet core (vEPC) market to register a CAGR of almost 56%. With a focus on identifying dominant industry influencers, Technavio\u2019s reports present a detailed study by the way of synthesis, and summation of data from multiple sources. This report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.\n \n \n \nThe market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Affirmed Networks, Athonet Srl, Cisco Systems Inc., Huawei Investment & Holding Co. Ltd., Mavenir Systems Inc., NEC Corp., Nokia Corp., Samsung Electronics Co. Ltd., Telefonaktiebolaget LM Ericsson, and ZTE Corp. are some of the major market participants. The rising use of multimedia services will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments, while maintaining their positions in the slow-growing segments.\n \n \n \nVirtualized Evolved Packet Core (vEPC) Market is segmented as below:\n \n \n \n \n \nTo help businesses improve their market position, the   provides a detailed analysis of around 25 vendors operating in the market. Some of these vendors include Affirmed Networks, Athonet Srl, Cisco Systems Inc., Huawei Investment & Holding Co. Ltd., Mavenir Systems Inc., NEC Corp., Nokia Corp., Samsung Electronics Co. Ltd., Telefonaktiebolaget LM Ericsson, and ZTE Corp.\n \nThe report also covers the following areas:\n \nMarket trends such as the increased demand for VoLTE are likely to emerge as one of the primary drivers of the market. However, factors such as complications associated with the deployment of vEPC as a solution may threaten the growth of the market.\n \n \n \n \n \nBacked with competitive intelligence and benchmarking, our research reports on the virtualized evolved packet core (vEPC) market are designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Solar PV Balance Of Systems Market Will Showcase Negative Impact During 2020-2024 | Increasing Investments In Renewable Energy to Boost the Market Growth | Technavio", "dates": ["2020-10-17T03:30:00Z"], "links": "https://www.businesswire.com/news/home/20201016005494/en/Solar-PV-Balance-Of-Systems-Market-Will-Showcase-Negative-Impact-During-2020-2024-Increasing-Investments-In-Renewable-Energy-to-Boost-the-Market-Growth-Technavio", "content": "LONDON--( )--Technavio has been monitoring the solar pv balance of systems market and it is poised to grow by $ 42.17 bn during 2020-2024, progressing at a CAGR of 16% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.\n \n \n \nThe market is fragmented, and the degree of fragmentation will accelerate during the forecast period. ABB Ltd., Eaton Corp. Plc, Golden Concord Holdings Ltd., Huawei Investment & Holding Co. Ltd., Prysmian Spa, ReneSola Ltd., Schneider Electric SE, SMA Solar Technology AG, Sungrow Power Supply Co. Ltd., and Unirac Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.\n \n \n \n \n \nIncreasing investments in renewable energy has been instrumental in driving the growth of the market. However, rising competition from other sources of energy might hamper market growth.\n \n \n \n \n \nSolar PV Balance Of Systems Market is segmented as below:\n \n \n \nTechnavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The  report covers the following areas:\n \nThis study identifies as one of the prime reasons driving the Solar PV Balance Of Systems Market growth during the next few years.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTechnavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Dr. Reddy\u2019s and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in India", "dates": ["2020-10-17T10:44:00Z"], "links": "https://www.businesswire.com/news/home/20201017005007/en/Dr.-Reddy%E2%80%99s-and-RDIF-receive-approval-to-conduct-clinical-trial-for-Sputnik-V-vaccine-in-India", "content": "HYDERABAD, India--( )--Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia\u2019s sovereign wealth fund, today announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study.\n \nEarlier in September 2020, Dr. Reddy\u2019s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy\u2019s upon regulatory approval in India.\n \n  Dr. Reddy\u2019s Laboratories, said \u201cThis is a significant development that allows us to commence the clinical trial in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.\u201d\n \n , said, \u201cWe are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial. This data will further strengthen the clinical development of Sputnik V vaccine in India.\u201d\n \nOn August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world\u2019s first registered vaccine against COVID-19 based on the human adenoviral vectors platform. Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000. Additionally, phase 3 clinical trial of the vaccine has commenced in the UAE last week.\n \n  Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products \u2013 Dr. Reddy\u2019s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy\u2019s operates in markets across the globe. Our major markets include \u2013 USA, India, Russia & CIS countries, and Europe. For more information, log on to:  \n \n ) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF\u2019s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia\u2019s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at  \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40 \u5b89\u5fc3\u5b89\u5168\u306a\u6ede\u5728\u3092\u63d0\u4f9b\u3059\u308b\u305f\u3081\u306e\u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u3092\u767a\u8868", "dates": ["2020-10-17T03:34:00Z"], "links": "https://www.businesswire.com/news/home/20201016005703/ja", "content": "\u9999\u6e2f--( )--\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4)--\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40\u306f\u3001\u9999\u6e2f\u306e\u4e3b\u8981\u306a\u9069\u5408\u6027\u8a55\u4fa1\u6a5f\u95a2\u306e\u4e00\u3064\u3067\u3042\u308b\u9999\u6e2f\u54c1\u8cea\u4fdd\u8a3c\u5c40\uff08HKQAA\uff09\u3068\u63d0\u643a\u3057\u3001\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\uff08Covid-19\uff09\u611f\u67d3\u5bfe\u7b56\u306e\u53d6\u308a\u7d44\u307f\u3092\u5927\u5e45\u306b\u5f37\u5316\u3059\u308b\u305f\u3081\u306e\u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\n \n\u9999\u6e2f\u3067\u306f\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u306e\u767a\u751f\u4ee5\u6765\u3001\u4e16\u754c\u3067\u3082\u6700\u9ad8\u6c34\u6e96\u306e\u885b\u751f\u5bfe\u7b56\u3092\u5e02\u6c11\u3068\u4f01\u696d\u304c\u4e00\u4e38\u3068\u306a\u3063\u3066 \u5c0e\u5165\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u89b3\u5149\u7523\u696d\u3067\u306f\u7279\u306b\u3001\u65e5\u5e38\u696d\u52d9\u306b\u9ad8\u5ea6\u306a\u6d88\u6bd2\u6280\u8853\u3092\u5c0e\u5165\u3059\u308b\u3053\u3068\u3067\u3001\u611f\u67d3\u62e1\u5927\u9632\u6b62\u306b\u7a4d\u6975\u7684\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\n \n\u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u306f\u3001\u9999\u6e2f\u3078\u306e\u30a4\u30f3\u30d0\u30a6\u30f3\u30c9\u65c5\u884c\u306e\u518d\u958b\u306b\u5411\u3051\u3066\u3001\u73fe\u5730\u306e\u5ba2\u3084\u9999\u6e2f\u3078\u306e\u89b3\u5149\u5ba2\u304c\u3088 \u308a\u5bb9\u6613\u306b\u7406\u89e3\u3057\u8a8d\u8b58\u3067\u304d\u308b\u3088\u3046\u306a\u3001\u6a19\u6e96\u5316\u3055\u308c\u305f\u611f\u67d3\u62e1\u5927\u9632\u6b62\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u89b3\u5149\u696d\u306b\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\n \n\u672c\u8981\u9805\u306f\u3001\u30b7\u30e7\u30c3\u30d4\u30f3\u30b0\u30e2\u30fc\u30eb\u3001\u30db\u30c6\u30eb\u3001\u30ec\u30b9\u30c8\u30e9\u30f3\u3001\u5c0f\u58f2\u696d\u3001\u30d0\u30b9\u4f1a\u793e\u3001\u89b3\u5149\u65bd\u8a2d\u3001\u65c5\u884c\u4ee3\u7406\u5e97\u306a\u3069\u304c\u5bfe\u8c61\u3068\u306a\u308a\u307e\u3059\u3002\u53c2\u52a0\u3059\u308b\u4f01\u696d\u3084\u5e97\u8217\u306f\u3001\u4e00\u9023\u306e\u885b\u751f\u304a\u3088\u3073\u611f\u67d3\u62e1\u5927\u9632\u6b62\u7b56\u3092\u9075\u5b88\u3059\u308b\u3053\u3068\u304c\u6c42\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002\uff08  \uff09 \u8981\u4ef6\u3092\u6e80\u305f\u3057\u305f\u4f01\u696d\u3084\u3001\u5e97\u8217\u306e\u8a73\u7d30\u306f HKQAA \u306e\u30b5\u30a4\u30c8\uff08  \uff09\u306b\u516c\u8868\u3055\u308c\u307e\u3059\u3002\u307e\u305f\u4e8b\u696d\u8005\u306f\u3001\u672c\u5b9f\u65bd\u8981\u9805\u3078\u306e\u53c2\u52a0\u3092\u793a\u3059\u30ed\u30b4\u3092\u63b2\u793a\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002 HKQAA \u306f\u3001\u7d99\u7d9a\u7684\u306b\u53c2\u52a0\u4e8b\u696d\u8005\u3078\u306e\u629c\u304d\u6253\u3061\u306e\u8a2a\u554f\u3092\u884c\u3044\u307e\u3059\u3002\n \n\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40\u4f1a\u9577\u306e\u30d1\u30f3\u30fb\u30e6\u30a6\u30ab\u30a4\uff08Pang Yiu-kai/\u5f6d\u8000\u4f73\uff09\u306f\u3001\u4ee5\u4e0b\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\n \n\u300c\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u306e\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u306b\u3088\u308a\u3001\u4e16\u754c\u306e\u89b3\u5149\u7523\u696d\u306b\u306f\u30cb\u30e5\u30fc\u30ce\u30fc\u30de\u30eb\u304c\u3082\u305f\u3089\u3055\u308c\u3001\u516c\u8846\u306e\u885b\u751f\u3068\u5b89\u5168\u304c\u65c5\u884c\u8005\u306b\u3068\u3063\u3066\u306e\u6700\u91cd\u8981\u4e8b\u9805\u3068\u306a\u308a\u307e\u3057\u305f\u3002\u591a\u304f\u306e\u56fd\u969b\u7684\u306a\u65c5\u884c\u30fb\u89b3\u5149\u56e3\u4f53\u3067\u306f\u3059\u3067\u306b\u885b\u751f\u7ba1\u7406\u3068\u611f\u67d3\u75c7\u5bfe\u7b56\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u7b56\u5b9a\u3057\u3066\u3044\u307e\u3059\u3002\u5404\u5206\u91ce\u3067\u306e\u885b\u751f\u5bfe\u7b56\u3092\u6a19\u6e96\u5316\u3059\u308b\u3053\u3068\u3067\u3001\u9999\u6e2f\u5168\u57df \u3067\u611f\u67d3\u62e1\u5927\u9632\u6b62\u7b56\u3092\u5f37\u5316\u3057\u3066\u3044\u308b\u3053\u3068\u304c\u89b3\u5149\u5ba2\u306b\u7406\u89e3\u3044\u305f\u3060\u3051\u308b\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002\n \n\u6211\u3005\u304c\u65c5\u884c\u696d\u754c\u306e\u7686\u69d8\u306b\u610f\u898b\u3092\u4f3a\u3063\u305f\u3068\u3053\u308d\u30011,800 \u4ee5\u4e0a\u306e\u4f01\u696d\u3084\u5c0f\u58f2\u5e97\u3088\u308a\u3001\u3053\u306e\u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u3078\u306e\u95a2\u5fc3\u304c\u5bc4\u305b\u3089\u308c\u3001\u5927\u5909\u3046\u308c\u3057\u304f\u601d\u3063\u3066\u304a\u308a\u307e\u3059\u3002\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40\u306f\u3001\u4eca\u5f8c\u3082\u3001\u89b3\u5149\u7523\u696d\u3084\u95a2\u9023\u5206\u91ce\u3067\u306e\u611f\u67d3\u62e1\u5927\u9632\u6b62\u7b56\u306e\u63a8\u9032\u3092\u5f37\u5316\u3057\u3001\u9999\u6e2f\u304c\u5065\u5eb7\u3067\u5b89\u5168\u306a\u65c5\u884c\u5148\u3068\u3067\u3042\u308b\u3068\u3044\u3046\u30a4\u30e1\u30fc\u30b8\u3092\u78ba\u7acb\u3057\u3001\u65c5\u884c\u8005\u306e\u9999\u6e2f\u3078\u306e\u65c5\u884c\u3078\u306e\u4fe1\u983c\u611f\u3092\u9ad8\u3081\u3066\u3044\u304d\u307e\u3059\u3002\u300d\n \n\u9999\u6e2f\u54c1\u8cea\u4fdd\u8a3c\u5c40\u306e\u30db\u30fc\uff08Ir C S Ho/\u4f55\u5fd7\u8aa0\uff09\u4f1a\u9577\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\n \n\u300c\u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u306e\u7b56\u5b9a\u306b\u3042\u305f\u308a\u3001\u9999\u6e2f\u54c1\u8cea\u4fdd\u8a3c\u5c40\u306f\u9999\u6e2f\u653f\u5e9c\u306e\u885b\u751f\u7f72\u885b\u751f\u9632\u8b77\u30bb\u30f3\u30bf\u30fc\u3068\u98df \u7269\u74b0\u5883\u885b\u751f\u7f72\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3092\u53c2\u8003\u306b\u3057\u307e\u3057\u305f\u3002\u6211\u3005\u306f\u3001\u89b3\u5149\u696d\u754c\u306b\u304a\u3051\u308b\u885b\u751f\u7ba1\u7406\u3068\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9 \u611f\u67d3\u62e1\u5927\u9632\u6b62\u7b56\u306e\u6210\u529f\u4e8b\u4f8b\u3092\u4fc3\u9032\u3057\u3001\u5c02\u9580\u7684\u304b\u3064\u516c\u5e73\u306a\u5be9\u67fb\u3067\u8a55\u4fa1\u3059\u308b\u3053\u3068\u3067\u3001\u6d88\u8cbb\u3084\u65c5\u884c\u306b\u5bfe\u3059\u308b\u65c5 \u884c\u8005\u306e\u5b89\u5fc3\u611f\u3092\u547c\u3073\u623b\u3059\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u304a\u308a\u307e\u3059\u3002\u4eca\u56de\u3001\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40\u3068\u63d0\u643a\u3057\u3001\u304a\u4e92\u3044\u306e\u5f37\u307f\u3092\u751f\u304b \u3057\u3066\u3001\u89b3\u5149\u696d\u754c\u5168\u4f53\u306e\u7d99\u7d9a\u7684\u306a\u6539\u5584\u3092\u63a8\u9032\u3057\u3001\u30cb\u30e5\u30fc\u30ce\u30fc\u30de\u30eb\u306e\u4e2d\u3067\u65b0\u3057\u3044\u885b\u751f\u7fd2\u6163\u306e\u6587\u5316\u3092\u69cb\u7bc9\u3067\u304d\u308b \u3068\u4fe1\u3058\u3066\u3044\u307e\u3059\u3002\u300d\n \n\u9999\u6e2f\u653f\u5e9c\u89b3\u5149\u5c40\u306f\u73fe\u5728\u3001\u9999\u6e2f\u7279\u5225\u884c\u653f\u533a\u653f\u5e9c\u304a\u3088\u3073\u89b3\u5149\u696d\u754c\u3068\u5354\u529b\u3057\u3066\u3001\u9999\u6e2f\u3078\u306e\u65c5\u884c\u518d\u958b\u306b\u5411\u3051\u305f \u4e00\u9023\u306e\u30d7\u30ed\u30e2\u30fc\u30b7\u30e7\u30f3\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u9999\u6e2f\u3067\u306f\u3001\u69d8\u3005\u306a\u4f53\u9a13\u3084\u7279\u5178\u3092\u901a\u3058\u3066\u3001\u518d\u3073\u89b3\u5149\u5ba2\u3092\u304a\u8fce\u3048\u3059\u308b\u6e96\u5099\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002\n \n\u25c6 \u885b\u751f\u5bfe\u7b56\u57fa\u6e96\u5b9f\u65bd\u8981\u7db1\u306e\u8a73\u7d30\u306f\u3001\u9999\u6e2f\u54c1\u8cea\u4fdd\u8a3c\u5c40\u306e WEB \u30b5\u30a4\u30c8\u304b\u3089\u3054\u78ba\u8a8d\u3044\u305f\u3060\u3051\u307e\u3059\u3002 \n \n\u25c6\u672c\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306e\u753b\u50cf\u306f\u4e0b\u8a18\u3088\u308a\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9\u3044\u305f\u3060\u3051\u307e\u3059\u3002 \n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "ROSEN, TRUSTED INVESTOR COUNSEL, Reminds YayYo, Inc. Investors of Important Deadline in Federal Securities Class Action \u2013 YAYO", "dates": ["2020-10-17T17:15:00Z"], "links": "https://www.businesswire.com/news/home/20201017005004/en/ROSEN-TRUSTED-INVESTOR-COUNSEL-Reminds-YayYo-Inc.-Investors-of-Important-Deadline-in-Federal-Securities-Class-Action-%E2%80%93-YAYO", "content": "NEW YORK--( )--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of YayYo, Inc. (OTC: YAYO) pursuant and/or traceable to the registration statement and related prospectus (collectively, the \u201cRegistration Statement\u201d) issued in connection with YayYo\u2019s November 2019 initial public offering (the \u201cIPO\u201d) of the important November 9, 2020 lead plaintiff deadline in the federal class action commenced by the firm. The lawsuit seeks to recover damages for YayYo investors under the federal securities laws.\n \nTo join the YayYo class action, go to   or call Phillip Kim, Esq. toll-free at 866-767-3653 or email   or   for information on the class action.\n \nAccording to the lawsuit, the Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) defendant El-Batrawi continued to exercise supervision, authority, and control over YayYo, and was intimately involved, on a day-to-day basis, with the business, operations, and finances of the Company, including assisting the Underwriter Defendants in marketing YayYo's IPO; (2) defendant El-Batrawi never sold the 12,525,000 \u201cPrivate Shares\u201d and continued to own a controlling interest in YayYo despite the NASDAQ\u2019s insistence that he retain less than a 10% equity ownership interest in connection with the listing agreement; (3) defendants promised certain creditors of YayYo that in exchange to their agreeing to purchase shares in the IPO \u2013 in order to permit the Underwriter defendants to close the IPO \u2013 YayYo would repurchase those shares after the IPO; (4) defendants intended to repurchase shares purchased by creditors of YayYo in the IPO using IPO proceeds: (5) YayYo owed its former President, CEO, and Director a half of million dollars at the time of the IPO; (6) YayYo owed SRAX, Inc. (formerly Social Reality, Inc.) $426,286 in unpaid social media costs, most of which was more than a year overdue as payment had been delayed while YayYo attempted to complete its IPO; and (7) as a result, defendants\u2019 statements about the Company\u2019s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.\n \nA class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court  . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to   or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at   or  .\n \nNO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR\u2019S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.\n \nFollow us for updates on LinkedIn:   or on Twitter:   or on Facebook:  .\n \nRosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm\u2019s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "High Protein-Based Food Market will Showcase Positive Impact during 2020-2024 | Shift In Preference Toward Natural And Herbal Products to Boost the Market Growth | Technavio", "dates": ["2020-10-17T03:45:00Z"], "links": "https://www.businesswire.com/news/home/20201016005501/en/High-Protein-Based-Food-Market-will-Showcase-Positive-Impact-during-2020-2024-Shift-In-Preference-Toward-Natural-And-Herbal-Products-to-Boost-the-Market-Growth-Technavio", "content": "LONDON--( )--Technavio has been monitoring the high protein-based food market and it is poised to grow by USD 27.49 billion during 2020-2024, progressing at a CAGR of 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.\n \n \n \nThe market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Clif Bar & Co., Glanbia Nutritionals Inc., GlaxoSmithKline Plc, Hormel Foods Corp., Iovate Health Sciences International Inc., Kellogg Co., Monster Beverage Corp., PepsiCo Inc., and The Coca Cola Co. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.\n \n \n \n \n \nShift in preference toward natural and herbal products has been instrumental in driving the growth of the market. However, stringent government regulations might hamper market growth.\n \n \n \n \n \nHigh Protein-Based Food Market is segmented as below:\n \n \n \nTechnavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The  report covers the following areas:\n \nThis study identifies the emergence of non-traditional fitness activities as one of the prime reasons driving the High Protein-Based Food Market growth during the next few years.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTechnavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "Global Poultry Eggs Market | Awareness Campaigns about Health Benefits of Eggs to Boost Market Growth | Technavio", "dates": ["2020-10-17T03:50:00Z"], "links": "https://www.businesswire.com/news/home/20201016005498/en/Global-Poultry-Eggs-Market-Awareness-Campaigns-about-Health-Benefits-of-Eggs-to-Boost-Market-Growth-Technavio", "content": "LONDON--( )--The global poultry eggs market size is poised to grow by USD 44.80 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic.  \n \nThe poultry eggs market is driven by the rising awareness campaigns about the health benefits of poultry eggs. Eggs are a popular choice of protein for a majority of the global population, as they are affordable and healthy. Moreover, egg yolks are a significant source of vitamins, minerals, and fat. They contain fat-soluble vitamin D and are naturally high in choline. Choline promotes normal cell activity, liver function, and the transportation of nutrients throughout the body. It also contributes to fetal brain development and helps prevent congenital disabilities. Therefore, to promote such benefits, several campaigns across the world are promoting egg consumption. For instance, the US government is promoting egg consumption in schools as a part of its National School Lunch Program and the Supplemental Nutrition Assistance Program. Thus, with such initiatives, the market for poultry eggs is expected to showcase a positive outlook during the forecast period.\n \n \n \n \n \n \n \n \n \n \n \nCurrently, major retailers across the world are introducing their brands of egg products to capitalize on the growing demand for poultry egg products among consumers. Private label egg products, which are affordable, are becoming popular among consumers. These products are stocked at retail stores and are available at prices lower than those of branded products. Price-sensitive consumers are more likely to purchase private label egg products because of their low cost. Therefore, it is expected that private label brands will boost the growth for the global poultry eggs market during the forecast period.\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio\u2019s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio\u2019s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.\n"},
{"site": "businesswire : A BERKSHIRE HATHAWAY COMPANY", "headlines": "COVID-19 Impact and Recovery Analysis | Maintenance Repair and Operations Services Industry Procurement Intelligence Report Forecasts Spend Growth of Over USD 87 Billion | SpendEdge", "dates": ["2020-10-17T05:30:00Z"], "links": "https://www.businesswire.com/news/home/20201016005528/en/COVID-19-Impact-and-Recovery-Analysis-Maintenance-Repair-and-Operations-Services-Industry-Procurement-Intelligence-Report-Forecasts-Spend-Growth-of-Over-USD-87-Billion-SpendEdge", "content": "LONDON--( )--The Global Maintenance Repair and Operations Services Industry is poised to experience spend growth of more than USD 87 billion between 2020-2024 at a CAGR of over 2.54%. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic.  \n \n \n \nSpendEdge's reports now include an in-depth complimentary analysis of the COVID-19 impact on procurement and the latest market data to help your company overcome sourcing challenges. Our   offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.\n \n \n \n \n \n \n \n \n \n \n \n \n \nThis Maintenance Repair and Operations Services Industry procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.\n \n -  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.    \n"}
]